|
2C-G-NBOMe
25G-NBOMe (NBOMe-2C-G) is a derivative of the phenethylamine hallucinogen 2C-G, which acts as a highly potent partial agonist for the human 5-HT2A receptor. Legality Sweden The Riksdag added 25G-NBOMe to Narcotic Drugs Punishments Act under ''swedish schedule I'' (''"substances, plant materials and fungi which normally do not have medical use"'') as of January 16, 2015, published by Medical Products Agency (MPA) in regulation ''LVFS 2014:11'' listed as 25G-NBOMe, and 2-(2,5-dimetoxi-3,4-dimetylfenyl)-N-(2-metoxibensyl)etanamin. United Kingdom See also * 2CBCB-NBOMe (NBOMe-TCB-2) * 2CBFly-NBOMe (NBOMe-2CB-Fly) * 2C-C-NBOMe (NBOMe-2CC) * 25B-NBOMe (NBOMe-2CB) * 25I-NBOMe (NBOMe-2CI) * 25I-NBMD (NBMD-2CI) * 25B-NBOH * 25I-NBOH 25I-NBOH (NBOH-2CI, Cimbi-27, 2-C-I-NBOH) is a derivative of the phenethylamine-derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University. Pharmacology 25I-NBOH acts as a potent agonist of the 5HT2A receptor, with ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Phenethylamine
Phenethylamine (PEA) is an organic compound, natural monoamine alkaloid, and trace amine, which acts as a central nervous system stimulant in humans. In the brain, phenethylamine regulates monoamine neurotransmission by binding to trace amine-associated receptor 1 (TAAR1) and inhibiting vesicular monoamine transporter 2 (VMAT2) in monoamine neurons. To a lesser extent, it also acts as a neurotransmitter in the human central nervous system. In mammals, phenethylamine is produced from the amino acid L-phenylalanine by the enzyme aromatic L-amino acid decarboxylase via enzymatic decarboxylation. In addition to its presence in mammals, phenethylamine is found in many other organisms and foods, such as chocolate, especially after microbial fermentation. Phenethylamine is sold as a dietary supplement for purported mood and weight loss-related therapeutic benefits; however, in orally ingested phenethylamine, a significant amount is metabolized in the small intestine by monoa ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
2CBCB-NBOMe
2CBCB-NBOMe (NBOMe-TCB-2) is a compound indirectly derived from the phenethylamine series of hallucinogens, which was discovered in 2007 at Purdue University as part of the ongoing research program of the team led by David Nichols focusing on the mapping of the specific amino acid residues responsible for ligand binding to the 5HT2A receptor. 2CBCB-NBOMe acts as a potent and selective agonist for the 5-HT2A and 5-HT2C receptors, with a Ki of 0.27 nM at the human 5-HT2A receptor, a similar potency to other agonists such as TCB-2 TCB-2 is a hallucinogen discovered in 2006 by Thomas McLean working in the lab of David Nichols at Purdue University. It is a conformationally-restricted derivative of the phenethylamine 2C-B, also a hallucinogen, and acts as a potent agonist ..., NBOMe-2C-I and Bromo-DragonFLY. Analogues and derivatives Legality United Kingdom United States 2CBCB-NBOMe is a controlled substance in Vermont as of January 2016. References 5-HT2A ago ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
25I-NBOH
25I-NBOH (NBOH-2CI, Cimbi-27, 2-C-I-NBOH) is a derivative of the phenethylamine-derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University. Pharmacology 25I-NBOH acts as a potent agonist of the 5HT2A receptor, with a Ki of 0.061 nM at the human 5HT2A receptor, similar to the better-known compound 25I-NBOMe, making it some twelve times the potency of 2C-I itself. Although ''in vitro'' tests show this compound acts as an agonist, animal studies to confirm these findings have not been reported. While the ''N''-benzyl derivatives of 2C-I had significantly increased binding to 5HT2A receptor fragments, compared to 2C-I, the ''N''-benzyl derivatives of DOI were less active compared to DOI. 25I-NBOH is notable as one of the most selective agonist ligands for the 5-HT2A receptor with an EC50 value of 0.074 nM with more than 400 times selectivity over the 5-HT2C receptor. Analytical chemistry 25I-NBOH is a labile molecule which fragments into ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
25B-NBOH
25B-NBOH (2C-B-NBOH, NBOH-2C-B) is a derivative of the phenethylamine derived hallucinogen 2C-B which has been sold as a designer drug A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. D .... It acts as a potent serotonin receptor agonist with similar affinity to the better-known compound 25B-NBOMe at 5-HT2A and 5-HT2C receptors with values of 8.3 and 9.4, respectively. Legal status Sweden The Riksdag added 25B-NBOH to Narcotic Drugs Punishments Act under Swedish Schedule I (''"substances, plant materials and fungi which normally do not have medical use"'') as of January 26, 2016, published by Medical Products Agency (MPA) in regulation ''HSLF-FS 2015:35'' listed as 25B-NBOH, and 2-( -(4-bromo-2,5-dimetoxifenyl)etylaminoetyl)fenol. United Kingdom Analogues and derivatives ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
25I-NBMD
25I-NBMD (NBMD-2C-I, Cimbi-29) is a derivative of the phenethylamine hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent partial agonist for the 5HT2A receptor Receptor may refer to: *Sensory receptor, in physiology, any structure which, on receiving environmental stimuli, produces an informative nerve impulse *Receptor (biochemistry), in biochemistry, a protein molecule that receives and responds to a n ... with a Ki of 0.049 nM at the human 5HT2A receptor. The corresponding 4-bromo analogue 25B-NBMD has been used for molecular dynamics studies on the shape of the 5-HT2A receptor. Legality Sweden The Riksdag added 25I-NBMD to Narcotic Drugs Punishments Act under ''swedish schedule I'' (''"substances, plant materials and fungi which normally do not have medical use"'') as of January 16, 2015, published by Medical Products Agency (MPA) in regulation ''LVFS 2014:11'' listed as 25I-NBMD, and 2-(4-jodo-2,5-dimetoxifen ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
25I-NBOMe
25I-NBOMe (2C-I-NBOMe, Cimbi-5, Smiles and also shortened to "25I") is a synthetic hallucinogen that is used in biochemistry research for mapping the brain's usage of the type 2A serotonin receptor; it is also sometimes used for recreational purposes. A derivative of the substituted phenethylamine 2C-I family, it is the most well-known member of the 25-NB family. It was discovered in 2003 by chemist Ralf Heim at the Free University of Berlin, who published his findings in his PhD dissertation. The compound was subsequently investigated by a team at Purdue University led by David Nichols. The carbon-11 labelled version of 25I-NBOMe, 1C/sup>Cimbi-5, was synthesized and validated as a radiotracer for positron emission tomography (PET) in Copenhagen. Being the first 5-HT2A receptor full agonist PET radioligand, 1C/sup>-CIMBI-5 shows promise as a more functional marker of these receptors, particularly in their high affinity states. Street and media nicknames for this drug ar ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
